Gordon Dougan

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Gordon Dougan
Alma materUniversity of Sussex[1]
Scientific career
ThesisAn Analysis of the Structure and Function of Plasmid ColE1 (1977)
Doctoral advisorDavid Sherratt
Doctoral studentsMark Pallen, Kat Holt

Gordon Dougan is Head of Pathogen Research and a member of the Board of Management at the Wellcome Trust Sanger Institute (WTSI) in Cambridge, United Kingdom.[4] He is also an Honorary Professor at the University of Cambridge and a Fellow of Wolfson College, Cambridge. During his career, Dougan has pioneered work on enteric diseases and been heavily involved in the movement to improve vaccine usage in developing countries. In this regard he was recently voted as one of the top ten most influential people in the vaccine world by people working in the area.[5]


He was educated in his home town of Scunthorpe in England, attending Henderson Avenue Junior School, Scunthorpe Grammar School and John Leggott Sixth Form College. He graduated with a degree in Biochemistry and received his PhD from the University of Sussex. Gordon completed postdoctoral research at the University of Washington (Seattle) in the laboratory of Professor Stanley Falkow.


Dougan's research team studies enteric pathogens with a strong emphasis on basic pathogenic mechanisms and immunology.[6][7][8][9][10][11][12][13][14] He has a particular interest in using genomics to study host/pathogens interactions, in particular using Salmonella enterica serovar Typhi, the cause of typhoid. He has extensive experience working both in industry and in academia. Before moving to the WTSI he was the Director of the Centre for Molecular Microbiology and Infection at the Imperial College London and a Professor of Physiological Biochemistry. There he was responsible for securing multimillion-pound funding for a new building in Kensington and providing infrastructure for the science.


Throughout his career Dougan has served as a referee, advisor and consultant for numerous institutions, universities, boards, committees and other organisations. He was a trustee of the International Vaccine Institute in Korea and has worked with other global agencies including the World Health Organization and the Global Alliance for Vaccine and Innovations (now GAVI Alliance). He was elected a Fellow of the Academy of Medical Sciences in 2002,[15] is a member of the European Molecular Biology Organisation and was elected a Fellow of the Royal Society in 2012.[16]

Dougan was a lecturer in the Moyne Institute in Trinity College, Dublin[citation needed] and then worked for over ten years in industry developing vaccines and novel drugs at the Wellcome Foundation (now GSK). He has participated in early and late clinical studies on several vaccines and is an expert in vaccinology/pathogenic mechanisms, specialising on the immunology of mucosal vaccines and molecular basis of infection. He has been Chair of the Novartis Vaccines & Diagnostics Scientific Advisory Board and has spun out a number of companies. He has published over 400 research papers, edited several books and has sat on the editorial boards of a number of prestigious journals.[9][17]

Awards and honours[edit]

Dougan was elected a Fellow of the Royal Society in 2012. His nomination reads:

Gordon Dougan is distinguished through his investigations into how bacteria interact with and stimulate the mucosal surfaces of the body during infection. His work has focused on bacterial pathogens, principally Salmonella Typhi and other enteric bacteria and has exploited genetic manipulation of both the host and pathogen. He has made important contributions to basic studies on the molecular basis of the infection process, genomics and to the development of practical vaccines.[2]

He was elected a member of the European Molecular Biology Organization (EMBO) in 2011.[3]

Personal life[edit]

He has been a lifelong supporter of Scunthorpe United and is a keen beekeeper.[18]


  1. ^ a b "DOUGAN, Prof. Gordon". Who's Who. ukwhoswho.com. 2014 (online Oxford University Press ed.). A & C Black, an imprint of Bloomsbury Publishing plc. (subscription or UK public library membership required) (subscription required)
  2. ^ a b "| Royal Society".
  3. ^ a b "The EMBO Pocket Directory" (PDF). European Molecular Biology Organization. Archived from the original (PDF) on 16 March 2015.
  4. ^ www-core (Web Team) (24 May 2013). "Professor Gordon Dougan – Wellcome Trust Sanger Institute". Sanger.ac.uk. Retrieved 6 June 2013.
  5. ^ Smale, Freya. "Who are the most influential people in vaccines?". Blogs.terrapinn.com. Retrieved 6 June 2013.
  6. ^ Rodriguez, A.; Vigorito, E.; Clare, S.; Warren, M. V.; Couttet, P.; Soond, D. R.; Van Dongen, S.; Grocock, R. J.; Das, P. P.; Miska, E. A.; Vetrie, D.; Okkenhaug, K.; Enright, A. J.; Dougan, G.; Turner, M.; Bradley, A. (2007). "Requirement of bic/microRNA-155 for Normal Immune Function". Science. 316 (5824): 608–11. Bibcode:2007Sci...316..608R. doi:10.1126/science.1139253. PMC 2610435. PMID 17463290.
  7. ^ Maloy, K. J.; Salaun, L.; Cahill, R.; Dougan, G.; Saunders, N. J.; Powrie, F. (2002). "CD4+CD25+ TR Cells Suppress Innate Immune Pathology Through Cytokine-dependent Mechanisms". Journal of Experimental Medicine. 197 (1): 111–9. doi:10.1084/jem.20021345. PMC 2193798. PMID 12515818.
  8. ^ Frankel, G.; Phillips, A. D.; Rosenshine, I.; Dougan, G.; Kaper, J. B.; Knutton, S. (1998). "Enteropathogenic and enterohaemorrhagic Escherichia coli: More subversive elements". Molecular Microbiology. 30 (5): 911–921. doi:10.1046/j.1365-2958.1998.01144.x. PMID 9988469. S2CID 10781807.
  9. ^ a b Gordon Dougan's publications indexed by the Scopus bibliographic database. (subscription required)
  10. ^ Mutreja, A.; Kim, D. W.; Thomson, N. R.; Connor, T. R.; Lee, J. H.; Kariuki, S.; Croucher, N. J.; Choi, S. Y.; Harris, S. R.; Lebens, M.; Niyogi, S. K.; Kim, E. J.; Ramamurthy, T.; Chun, J.; Wood, J. L. N.; Clemens, J. D.; Czerkinsky, C.; Nair, G. B.; Holmgren, J.; Parkhill, J.; Dougan, G. (2011). "Evidence for several waves of global transmission in the seventh cholera pandemic". Nature. 477 (7365): 462–465. Bibcode:2011Natur.477..462M. doi:10.1038/nature10392. PMC 3736323. PMID 21866102.
  11. ^ Okoro, C. K.; Kingsley, R. A.; Connor, T. R.; Harris, S. R.; Parry, C. M.; Al-Mashhadani, M. N.; Kariuki, S.; Msefula, C. L.; Gordon, M. A.; De Pinna, E.; Wain, J.; Heyderman, R. S.; Obaro, S.; Alonso, P. L.; Mandomando, I.; MacLennan, C. A.; Tapia, M. D.; Levine, M. M.; Tennant, S. M.; Parkhill, J.; Dougan, G. (2012). "Intracontinental spread of human invasive Salmonella Typhimurium pathovariants in sub-Saharan Africa". Nature Genetics. 44 (11): 1215–1221. doi:10.1038/ng.2423. PMC 3491877. PMID 23023330.
  12. ^ Zhou, Z; McCann, A; Weill, F. X.; Blin, C; Nair, S; Wain, J; Dougan, G; Achtman, M (2014). "Transient Darwinian selection in Salmonella enterica serovar Paratyphi a during 450 years of global spread of enteric fever". Proceedings of the National Academy of Sciences of the United States of America. 111 (33): 12199–204. Bibcode:2014PNAS..11112199Z. doi:10.1073/pnas.1411012111. PMC 4143038. PMID 25092320. open access
  13. ^ Achtman, M.; Wain, J.; Weill, F. O. X.; Nair, S.; Zhou, Z.; Sangal, V.; Krauland, M. G.; Hale, J. L.; Harbottle, H.; Uesbeck, A.; Dougan, G.; Harrison, L. H.; Brisse, S.; S. Enterica MLST Study Group (2012). Bessen, Debra E (ed.). "Multilocus Sequence Typing as a Replacement for Serotyping in Salmonella enterica". PLOS Pathogens. 8 (6): e1002776. doi:10.1371/journal.ppat.1002776. PMC 3380943. PMID 22737074. open access
  14. ^ www-core (Web team) (30 January 2013). "Microbial pathogenesis – Wellcome Trust Sanger Institute". Sanger.ac.uk. Retrieved 6 June 2013.
  15. ^ "The Academy of Medical Sciences | Directory of Fellows". Acmedsci.ac.uk. Retrieved 6 June 2013.
  16. ^ "Fellows of the". Royal Society. Retrieved 6 June 2013.
  17. ^ "Gordon Dougan – PubMed – NCBI". Ncbi.nlm.nih.gov. 25 March 2013. Retrieved 6 June 2013.
  18. ^ https://twitter.com/GordonDougan1/status/1348207648878055425